Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Svetlana Meisner"'
Autor:
Sine Buhl, Casper Steenholdt, Jørn Brynskov, Katrine Risager Christensen, Maria Dorn-Rasmussen, Ole Østergaard Thomsen, Klaus Bendtzen, Tobias Wirenfeldt Klausen, Jens Frederik Dahlerup, Niels Thorsgaard, Jørgen Jahnsen, Akbar Molazahi, Natalia Pedersen, Jens Kjeldsen, Sven Almer, Eva Efsen Dahl, Ida Vind, Annett Gerhardt Cannon, Jan Marsal, Taina Sipponen, Jørgen Steen Agnholt, Hendrika Adriana Linda Kievit, Synnøve Louise Aure, Lars Martinsen, Svetlana Meisner, Jane Møller Hansen, Mark Andrew Ainsworth
Publikováno v:
NEJM Evidence. 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45f57c30f6970e2832e23c1a8454a7d1
https://doi.org/10.1056/evidoa2200061
https://doi.org/10.1056/evidoa2200061
Autor:
Svetlana Meisner, Jørgen Jahnsen, Ida Vind, Klaus Bendtzen, Maria Dorn-Rasmussen, Lars Martinsen, Niels Thorsgaard, Sven Almer, Hendrika Adriana Linda Kievit, Jane Moeller, Sine Buhl, Taina Sipponen, Akbar Molazahi, Eva E. Dahl, Jens Kjeldsen, Mark A. Ainsworth, Katrine R. Christensen, Casper Steenholdt, Jens Frederik Dahlerup, Jan Marsal, Synn⊘ve L. Aure, J⊘rn Brynskov, Ole Østergaard Thomsen, Natalia Pedersen, Tobias Wirenfeldt Klausen, J⊘rgen Steen Agnholt, Annett G. Cannon
Publikováno v:
Gastroenterology. 160:S-151
Background It remains unknown whether infliximab (IFX) successfully can be discontinued once Crohn's disease (CD) patients have attained sustained, complete clinical, biochemical, and endoscopic remission. No randomized, placebo (PBO) controlled tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7fc9e29df48833feb17eaf2df2fc6c4
https://doi.org/10.1016/s0016-5085(21)01115-x
https://doi.org/10.1016/s0016-5085(21)01115-x